- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06458218
Impact of Multi-component Interventions on Populations With Mental Health Symptoms and High-risk COPD (POPMIX-MH)
Population Medicine Multimorbidity Interventions in Xishui on a High-Risk COPD Population With Mental Health Symptoms: A Cluster Randomized Controlled Trial
Study Participants: High-risk COPD population with mental health symptoms, defined as individuals whose score of COPD-SQ ≥ 16, whose age is 35 and above, and whose Warwick-Edinburgh Mental Well-being Scale <45 .
Intervention: We have constructed a pay-for-population mechanism for medical practitioners within the intervention townships to encourage them caring for population health. For study participants in the intervention arm, we will ask them to finish an online COPD-SQ questionnaire with notification of his or her COPD high risk status. For those with high-risk COPD population, we will provide face-to-face survey, simple physical examination, pulmonary function tests, and provide a multi-component intervention at baseline. For high-risk COPD population with mental health issues in the intervention arm, we provide community-based spirometry pulmonary function test (PFT) and education; If individuals whose post-bronchodilator FEV1/FVC<0.7, they will be spirometry-defined COPD patients and will be encouraged to seek treatment and medication to the superior hospitals. A CBT-based digital health intervention program, EmoEase, will be provided to our study participants with an intelligent mobile phone. Also health education in terms of mental health issues will be given. Additionally, we provide (1) a digital health intervention programs to smokers; (2) CBT-based health education for study participants with abnormal BMI; (3) active recruitment into National Essential Public Health Program in China for those with abnormal blood pressure and blood glucose. Intensive follow-ups will be conducted at month 3 (telephone interview), month 6 (face-to-face with full steps of physical examination), and month 12.
Comparison: Those who are assigned in the control arm, we will ask them to finish the same COPD-SQ online questionnaire with notification of his or her COPD high risk status and a face-to-face survey. No physical examinations, community-based pulmonary function tests will be given.
Outcomes: The primary outcomes are PHQ-9 scores for depression symptoms, GAD-7 symptoms for anxiety symptoms, and WEM-WBS score at month 12.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Guizhou
-
Zunyi, Guizhou, China
- Xishui County
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Aged 35 and above;
- High-risk COPD population, defined by score of COPD-SQ ≥ 16;
- Mental health issues, defined by WEM-WBS scale < 45;
- Local residents who stay within a township in the previous 3 months and plan to stay within the same township for the next 12 months.
Exclusion Criteria:
- Those who suffer from severe cognitive disorder or total loss of ability of daily living.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Intervention arm
We have constructed a pay-for-population mechanism to encourage medical workers caring for population health.
We will ask study populations to finish online COPD-SQ questionnaire with notification of his or her COPD high risk status.
For high-risk COPD population, we will provide a face-to-face survey and examination, and provide a multi-component intervention at baseline.
We give community-based spirometry pulmonary function test and education; If individuals who are COPD patients, they will be encouraged to seek treatment to the superior hospitals.
A CBT-based digital health program will be provided.
Also health education will be given.
Additionally, we provide (1) a digital health intervention programs to smokers; (2) CBT-based health education for the abnormal BMI; (3) active recruitment into National Essential Public Health Program for those with high blood pressure and blood glucose.
Intensive follow-ups will be conducted at month 3, 6, 12.
|
|
|
No Intervention: Control Arm
Those who are assigned in the control arm, we will ask them to finish the same COPD-SQ online questionnaire with notification of his or her COPD high risk status and a face-to-face survey.
No physical examinations, community-based pulmonary function tests will be given.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Depression Symptoms
Time Frame: 1 year
|
Definition: Emotional disorders, including sadness, loss, and anger; Variable type: Continuous; Measurement: PHQ-9; Introduction to PHQ-9: Patient Health Questionnaire- 9 items (PHQ-9), ranging from 0 to 27, the higher the score, the severer the depression symptoms for the respondents will be.
|
1 year
|
|
Anxiety Symptoms
Time Frame: 1 year
|
Definition: Unpleasant state of inner turmoil; Variable type: Continuous; Measurement: GAD-7; Introduction to GAD-7: General Anxiety Disorder - 7 (GAD-7), ranging from 0 to 21, the higher the score, the severer the anxiety symptoms for the respondents will be.
|
1 year
|
|
Warwick-Edinburgh Mental Well-being Scale, WEM -WBS
Time Frame: 1 year
|
Definition: Reflects overall mental health problems; Variable type: Continuous; Measurement: WEMWBS; Introduction to WEMWBS: Warwick-Edinburgh Mental Well-being Scale, ranging from 14 to 70, the lower the score, the worse one's general mental health will be.
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of chronic diseases controlled
Time Frame: 1 year
|
Definition: Among all 7 objectively measured health conditions (depression symptoms, anxiety symptoms, COPD, asthma, BMI, hypertension, type 2 diabetes), number of chronic diseases controlled; Variable type: Counting data; Measurement: Physical examination or validated scales.
|
1 year
|
|
FEV1 measurement
Time Frame: 1 year
|
Definition: Forced Expiratory Volume in one second (FEV1); Variable type: Continuous; Measurement: Pulmonary function test, portable spirometry;
|
1 year
|
|
COPD Screening
Time Frame: 1 year
|
Definition: Have you ever had a pulmonary function test?; Variable type: Binary; Measurement: Respondent's answer to the question;
|
1 year
|
|
Self-awareness of COPD
Time Frame: 1 year
|
Definition: Have you ever been diagnosed with COPD?; Variable type: Binary; Measurement: Respondent's answer to the question;
|
1 year
|
|
COPD-Knowledge
Time Frame: 1 year
|
Definition: COPD Knowledge Questionnaire; Variable type: Continuous; Measurement: Respondent's answer to the questions;
|
1 year
|
|
Treatment adherence
Time Frame: 1 year
|
Definition: Are you currently receiving a COPD treatment plan prescribed by a doctor or other healthcare professional?;
Variable type: Binary; Measurement: Respondent's answer to the question;
|
1 year
|
|
COPD control
Time Frame: 1 year
|
Definition: Has the number of acute exacerbations decreased in the past six months?; Variable type: Binary; Measurement: Respondent's answer to the question;
|
1 year
|
|
Blood pressure
Time Frame: 1 year
|
Definition: Systolic and diastolic blood pressure (mmHg); Variable type: Continuous; Measurement: Omron portable automatic blood pressure monitor;
|
1 year
|
|
Blood Glucose
Time Frame: 1 year
|
Definition: Reference standard for average plasma glucose concentration over a period of time; Variable type: Continuous; Measurement: Blood glucose meter;
|
1 year
|
|
Waist circumference
Time Frame: 1 year
|
Definition: Waist circumference (cm); Variable type: Continuous; Measurement: Soft measuring tape;
|
1 year
|
|
BMI
Time Frame: 1 year
|
Definition: Body mass index (BMI), weight divided by height squared (kg/m²); Variable type: Continuous; Measurement: Calculation;
|
1 year
|
|
HBP Screening
Time Frame: 1 year
|
Definition: Have you ever had your blood pressure measured by a doctor, nurse, or other healthcare professional?;
Variable type: Binary; Measurement: Respondent's answer to the question;
|
1 year
|
|
HBP Diagnosis
Time Frame: 1 year
|
Definition: Have you ever been diagnosed with hypertension by a doctor?; Variable type: Binary; Measurement: Respondent's answer to the question;
|
1 year
|
|
HBP Treatment
Time Frame: 1 year
|
Definition: Are you currently taking any antihypertensive medication prescribed by a doctor or other healthcare professional?
Variable type: Binary; Measurement: Respondent's answer to the question;
|
1 year
|
|
HBP Control
Time Frame: 1 year
|
Definition: Blood pressure within the normal range at the end-of-year follow-up; Variable type: Binary; Measurement: Blood pressure measurement
|
1 year
|
|
T2DM Screening
Time Frame: 1 year
|
Definition: Have you ever had your blood glucose measured by a doctor, nurse, or other healthcare professional?;
Variable type: Binary; Measurement: Respondent's answer to the question;
|
1 year
|
|
T2DM Diagnosis
Time Frame: 1 year
|
Definition: Have you ever been diagnosed with T2DM by a doctor?; Variable type: Binary; Measurement: Respondent's answer to the question;
|
1 year
|
|
T2DM Treatment
Time Frame: 1 year
|
Definition: Are you currently receiving a type 2 diabetes treatment plan prescribed by a doctor or other healthcare professional?;
Variable type: Binary; Measurement: Respondent's answer to the question;
|
1 year
|
|
T2DM Control
Time Frame: 1 year
|
Definition: Blood glucose within the normal range at the end-of-year follow-up; Variable type: Binary; Measurement: Blood glucose measurement;
|
1 year
|
|
Smoking Status
Time Frame: 1 year
|
Definition: Do you currently smoke?; Variable type: Binary; Measurement: Respondent's answer to the question;
|
1 year
|
|
Smoking Amount
Time Frame: 1 year
|
Definition: If yes, how many cigarettes do you smoke per day on average?; Variable type: Count; Measurement: Respondent's answer to the question;
|
1 year
|
|
Drinking Status
Time Frame: 1 year
|
Definition: Frequency of alcohol consumption in the past 3 months; Variable type: Categorical; Measurement: Respondent's answer to the question;
|
1 year
|
|
Sugar Consumption
Time Frame: 1 year
|
Definition: Frequency of consumption of sugary foods/drinks; Variable type: Categorical; Measurement: Respondent's answer to the question;
|
1 year
|
|
Salted Vegetables Consumption
Time Frame: 1 year
|
Definition: Frequency of consumption of salty vegetables; Variable type: Categorical; Measurement: Respondent's answer to the question;
|
1 year
|
|
Vegetable Consumption
Time Frame: 1 year
|
Definition: Frequency of consumption of vegetable; Variable type: Categorical; Measurement: Respondent's answer to the question;
|
1 year
|
|
CAT score
Time Frame: 1 year
|
Definition: CAT questionnaire for COPD patients; Variable type: Continuous; Measurement: Respondent's answer to the question; Introduction to CAT questionnaire: COPD Assessment Test (CAT) is a questionnaire for people with COPD.
It is designed to measure the impact of COPD on a person's life, and how this changes over time.
The scope ranges from 0 to 40, the higher the score, the worse the COPD conditions.
|
1 year
|
|
Self-rated health status
Time Frame: 1 year
|
Definition: General self-assessed health status; Variable type: Continuous; Measurement: EQ-5D scale; Introduction to EQ-5D-5L scale: The 5-level EQ-5D version (EQ-5D-5L) was introduced by the EuroQol Group in 2009 to improve the instrument's sensitivity and to reduce ceiling effects, as compared to the EQ-5D-3L.
The scale could be transferred to health utility value, ranging from 0 to 1 continuously.
0 represents death and 1 represents perfect health.
|
1 year
|
|
mMRC score
Time Frame: 1 year
|
Definition: mMRC questionnaire; Variable type: Categorical; Measurement: Respondent's answer to the question; Introduction to mMRC: Modified Medical Research Council, categorical value, level 0 represents a good respiratory condition, while the maximum level 4 represents a very bad respiratory condition.
|
1 year
|
|
Productivity Loss
Time Frame: 1 year
|
Definition: Productivity loss due to illness or health problems from Working Productivity and Activity Impairment-General Health Chinese version 2.0; Variable type: Continuous; Measurement: Respondent's answer to the question; WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity, i.e., worse outcomes, as follows: Questions:
Scores: Multiply scores by 100 to express in percentages. Percent work time missed due to health: Q2/(Q2+Q4) Percent impairment while working due to health: Q5/10 Percent overall work impairment due to health: Q2/(Q2+Q4)+[(1-(Q2/(Q2+Q4)))x(Q5/10)] Percent activity impairment due to health: Q6/10 |
1 year
|
|
Outpatient
Time Frame: 1 year
|
Definition: Outpatient visits and type of hospital; Variable type: Count; Measurement: Survey data/insurance/outpatient data;
|
1 year
|
|
Inpatient
Time Frame: 1 year
|
Definition: Inpatient visits and type of hospital; Variable type: Count; Measurement: Survey data/insurance/outpatient data;
|
1 year
|
|
Medical expenditure within a family over the past year
Time Frame: 1 year
|
Definition: Healthcare-related expenditures; Variable type: Continuous; Measurement: Survey data/insurance/outpatient/inpatient data;
|
1 year
|
|
Physical exercise
Time Frame: 1 year
|
Definition: Frequency of physical exercise; Variable type: Categorical; Measurement: Respondent's answer to the question;
|
1 year
|
|
Smoking Dependence
Time Frame: 1 year
|
Fagerström test for nicotine dependence (FTND) is a scale that measures the nicotine dependence of smokers, ranging from 0 to 10, the higher the value, the worse the nicotine dependence will be.
Heaviness Index of Smoking (HIS) could also be calculated using part of the scale, ranging from 0 to 6, and higher score means worse nicotine dependence.
|
1 year
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Simiao Chen, Ph.D., Peking Union Medical College
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- CAMS&PUMC-IEC-2024-043
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multimorbidity
-
Malin Olsen SyversenOslo University Hospital; Oslo University CollegeRecruiting
-
National Taiwan University HospitalActive, not recruiting
-
Hospital Galdakao-UsansoloHospital del Mar; Instituto de Salud Carlos III; Hospitales Universitarios Virgen... and other collaboratorsCompleted
-
Dartmouth-Hitchcock Medical CenterNational Library of Medicine (NLM)CompletedMultimorbidityUnited States
-
Central Jutland Regional HospitalCompleted
-
McMaster UniversityCompleted
-
Hospital de Clinicas de Porto AlegreNot yet recruitingMultimorbidityBrazil
-
Central Jutland Regional HospitalNot yet recruiting
-
Slagelse HospitalUniversity of CopenhagenRecruiting
-
Johns Hopkins UniversityEnrolling by invitationMultimorbidityUnited States
Clinical Trials on Multi-component Interventions
-
Duke-NUS Graduate Medical SchoolAga Khan University; International Centre for Diarrhoeal Disease Research,... and other collaboratorsUnknown
-
Hamad Medical CorporationPrimary Health Care Corporation, QatarActive, not recruiting
-
Fundación Eduardo AnituaCompleted
-
Chiba UniversityNovo Nordisk A/S; Delivery Associates; The Behavioural Insights TeamNot yet recruitingObesity | Physical Activity | Childhood Obesity | Nutrition | Quality of Life (QOL)Japan
-
VA Office of Research and DevelopmentNot yet recruitingTobacco Use Disorder | Serious Mental IllnessUnited States
-
Peking Union Medical CollegeChina-Japan Friendship HospitalActive, not recruitingMultimorbidity | Chronic Asthma | Population MedicineChina
-
George Washington UniversityCompletedPrEP | HIV Risk PerceptionUnited States
-
University of LiverpoolOswaldo Cruz Foundation; University of Warwick; National Institute for Health... and other collaboratorsCompletedEncephalitis | Meningitis | Abscess BrainIndia, Brazil, Malawi
-
University of Southern DenmarkActive, not recruitingNeck Pain | Shoulder Pain | Lifestyle
-
University of ValenciaRecruitingPhysical Activity | Music Intervention | Fundamental Motor SkillsSpain